Menopause and eye health softgels from Sirio to showcase at CPHI Barcelona

By Liza Laws

- Last updated on GMT

© Sirio
© Sirio

Related tags Softgel Contract research organization Pharmaceutical industry CPHI

CDMO, Sirio Europe, is launching two new softgels aimed at those who want to develop in the pharmaceutical consumer health space at this year’s CPHI in Barcelona.

The new formulations are designed, Sirio says, to meet rising demand for more natural actives particularly for menopause and improved eye health.

The company held a European GMP license for the production of pharmaceutical softgels in its German manufacturing site since 1996.

Sirio says the gels are part of a wider strategy to work with OTC brands and large pharmacy chains in Europe.

The new ready-to market formulations form part of a wider strategy to work with both over the counter (OTC) brands and large pharmacy chains looking to develop nutraceutical combinations in Europe.

Menopause and preventative eye health

Sara Lesina, general manager Europe at Sirio, said: “We see a trend with many pharma and OTC customers who are looking to enter the consumer health space with formulations targeting common health concerns like menopause and preventative eye health.

“They are attracted by the far shorter times to market and the increasing consumer spend in the category. However, these customers also want a reliable partner that can match both pharmaceutical and nutraceutical manufacturing standards and have the experience to guide them on what consumers desire.”

To help its partners innovate and advance to market faster, Sirio has created two ready-to-launch concepts especially for CPHI Barcelona.

The first is a menopause softgel, which the company says is in response to the wider market demands for plant-based products and contains evening primrose oil.

Plant-derived, vegan, gluten-free

The softgel also is made using the company’s Plantegrity technology meaning they are plant-derived and both vegan and gluten free. Each softgel will contain 500mg of evening primrose oil, with 45mg of Gamma Linolenic Acid (GLA) – known to help regulation of immunity, cholesterol and menstrual cycles, Sirio said.

Due to the rise in the amount of time people are using screens, the company says there has been a rise in demand. Sirio will introduce its special vision care complex which has a combination of lutein, zeaxanthin and astaxanthin. These ingredients are said to help maintain eye health and a recent study, the company says, showed the combination improved hand-eye coordination.  

Lesina added: “There is now a global drive towards exceptional quality and the highest manufacturing standards for nutraceuticals. Our ideal partners are those that share these values and are looking to develop products that have enhanced bioavailability, proven shelf life and, critically for a consumer facing product, far better organoleptic qualities.

“Not all nutraceutical products are created equal, and the way they are manufactured is often the discriminator between market success and lacklustre growth. It’s why the biggest brands trust Sirio globally.”

Related news

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more